RecruitingRecruiting
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
NCT07636811 · Alnylam Pharmaceuticals
In plain English
Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.
Official title
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
About this study
The purpose of the study is to evaluate the effect of mivelsiran in adult participants with early-stage DS-AD and to characterize the safety, tolerability, and pharmacodynamics (PD) of mivelsiran. The study will be conducted over 2 periods: a 24-month double-blind period and an optional 12-month open-label treatment extension (OLE) period. The estimated duration of study participation, inclusive of screening, treatment, and additional safety follow-up, is up to 39 months.
Eligibility criteria
Inclusion Criteria:
* Clinical diagnosis of Down-Syndrome (DS) associated with trisomy 21
* Positive amyloid PET scan
* Cognitively stable in the opinion of the investigator with no diagnosis of mild cognitive impairment (MCI) or dementia
* Seizures must be well controlled with no occurrence of seizures in the 6 months prior to screening
Exclusion Criteria:
* Has severe intellectual disability (ID)
* Has a history of DS regression disorder
* Has alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>2×upper limit of normal (ULN) at Screening
* Has estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m\^2 at Screening
* Has recently received an investigational agent
* Has had treatment with amyloid-targeting antibody
* Comorbidities such as obstructive sleep apnea and hypothyroidism that are not well controlled
Note: other protocol defined inclusion / exclusion criteria apply
Study design
Enrollment target: 58 participants
Allocation: randomized
Masking: quadruple
Age groups: adult
Timeline
Starts: 2026-08-17
Estimated completion: 2031-07-30
Last updated: 2026-11-18
Interventions
Drug: MivelsiranDrug: Placebo
Primary outcomes
- • Double-Blind Period: Change from baseline in brain amyloid burden measured in centiloids (CLs) (Up to 24 months)
Sponsor
Alnylam Pharmaceuticals · industry
Contacts & investigators
ContactAlnylam Clinical Trial Information Line · contact · clinicaltrials@alnylam.com · 1-877-ALNYLAM
ContactAlnylam Clinical Trial Information Line · contact · clinicaltrials@alnylam.com · 1-877-256-9526
InvestigatorMedical Director · study_director, Alnylam Pharmaceuticals
All locations (20)
Clinical Trial SiteRecruiting
Maitland, Florida, United States
Clinical Trial SiteRecruiting
Naples, Florida, United States
Clinical Trial SiteNot Yet Recruiting
Fishers, Indiana, United States
Clinical Trial SiteRecruiting
Indianapolis, Indiana, United States
Clinical Trial SiteRecruiting
Kansas City, Kansas, United States
Clinical Trial SiteRecruiting
St Louis, Missouri, United States
Clinical Trial SiteRecruiting
Cincinnati, Ohio, United States
Clinical Trial SiteNot Yet Recruiting
Cincinnati, Ohio, United States
Clinical Trial SiteNot Yet Recruiting
Nashville, Tennessee, United States
Clinical Trial SiteRecruiting
Nashville, Tennessee, United States
Clinical Trial SiteRecruiting
Beaumont, Texas, United States
Clinical Trial SiteNot Yet Recruiting
Madison, Wisconsin, United States
Clinical Trial SiteRecruiting
Madison, Wisconsin, United States
Clinical Trial SiteRecruiting
Barcelona, Spain
Clinical Trial SiteRecruiting
Dos Hermanas, Spain
Clinical Trial SiteRecruiting
Madrid, Spain
Clinical Trial SiteRecruiting
Pamplona, Spain
Clinical Trial SiteRecruiting
Seville, Spain
Clinical Trial SiteRecruiting
Valencia, Spain
Clinical Trial SiteRecruiting
London, United Kingdom